Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467999 · ClinicalTrials.gov registry record · Phase 1
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01467999 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 22 participants.
The verdict
NCT01467999, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving as compared to baseline.
Interventions
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467999
The ClinicalTrials.gov registry entry for NCT01467999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guanfacine is the first listed.
NCT01467999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467999 about?
NCT01467999 is a clinical study titled "Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence". The purpose of this study is to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving as compared to baseline.
What is the current status of trial NCT01467999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01467999?
The interventions under investigation include: Guanfacine (DRUG).
Who is sponsoring clinical trial NCT01467999?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.